← FDA DRUG APPROVALS

FDA ANDA · ANDA215798

JAVYGTOR

sapropterin dihydrochloride

Sponsor: DR REDDYS

APPLICATION
ANDA215798
TYPE
ANDA
ORIGINAL APPROVAL
2022-05-13
LATEST ACTION
2025-01-24
ROUTE
ORAL
DOSAGE FORM
FOR SOLUTION
MARKETING STATUS
Prescription

Products

SAPROPTERIN DIHYDROCHLORIDEPrescription
SAPROPTERIN DIHYDROCHLORIDE 500MG/PACKET · FOR SOLUTION · ORAL

Approval history

2025-01-24Labeling · Supplement 3 · standardAP
2024-03-15Labeling · Supplement 2 · standardAP
2022-09-26Labeling · Supplement 1 · standardAP
2022-05-13UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →